Abstract
Aza-modifications of phenanthroindolizidine and phenanthroquinolizidine alkaloids were firstly designed to produce two aza-analogues, 13a-azatylophorine and 14a-aza-7-methoxylcryptopleurine starting from hydrazine monohydrate with high overall yields, respectively. The synthesis highlighted that some kinds of reactions were ameliorated in methodology. The newly synthesized target molecules including their salt derivatives were evaluated for anticancer activities against the BEL-7402 human liver cancer cell line and MOLT-4 human leukemia cell line. They exhibit anticancer activities.
Keywords: 13a-azatylophorine, 14a-aza-7-methoxylcryptopleurine, phenanthroindolizidine, alkaloid, aza-modification, anticancer
Letters in Organic Chemistry
Title: Efficient Synthesis of Aza-Phenanthroindolizidine and Aza-Phenanthroquinolizidine and Anticancer Activities
Volume: 5 Issue: 5
Author(s): Kailiang Wang, Wenlong Wang, Qingmin Wang and Runqiu Huang
Affiliation:
Keywords: 13a-azatylophorine, 14a-aza-7-methoxylcryptopleurine, phenanthroindolizidine, alkaloid, aza-modification, anticancer
Abstract: Aza-modifications of phenanthroindolizidine and phenanthroquinolizidine alkaloids were firstly designed to produce two aza-analogues, 13a-azatylophorine and 14a-aza-7-methoxylcryptopleurine starting from hydrazine monohydrate with high overall yields, respectively. The synthesis highlighted that some kinds of reactions were ameliorated in methodology. The newly synthesized target molecules including their salt derivatives were evaluated for anticancer activities against the BEL-7402 human liver cancer cell line and MOLT-4 human leukemia cell line. They exhibit anticancer activities.
Export Options
About this article
Cite this article as:
Wang Kailiang, Wang Wenlong, Wang Qingmin and Huang Runqiu, Efficient Synthesis of Aza-Phenanthroindolizidine and Aza-Phenanthroquinolizidine and Anticancer Activities, Letters in Organic Chemistry 2008; 5 (5) . https://dx.doi.org/10.2174/157017808784872106
DOI https://dx.doi.org/10.2174/157017808784872106 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Virus Attachment and Entry Offer Numerous Targets for Antiviral Therapy
Current Pharmaceutical Design Cytotoxicity and Anti-proliferative Properties of Heterocyclic Compounds Derived from Progesterone
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
MicroRNA Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
Current Medicinal Chemistry Stimuli-responsive Drug Delivery Nanosystems: From Bench to Clinic
Current Nanomedicine A Comprehensive Review on SAR of Curcumin
Mini-Reviews in Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Triggered Activation and Release of Liposomal Prodrugs and Drugs in Cancer Tissue by Secretory Phospholipase A2
Current Drug Delivery Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery